Moderna’s chief financial officer Lorence Kim and chief medical officer Tal Zaks dumped the staggering value of stocks on Monday and Tuesday when the share price skyrocketed following the company’s announcement of promising results from its vaccine trial.
Kim exercised 241,000 options for $3 million Monday, then instantly sold them for $19.8 million, taking a tidy profit of $16.8 million, SEC filings seen by CNN Business show.
On Tuesday, Zaks exercised $1.5 million stock options before making a profit of $8.2 million when he immediately offloaded them for $9.77 million.
Stocks in Moderna surged as much as 30 percent Monday to $87 a share, after it released promising results of its COVID-19 vaccine trial
The biotech company released promising results from its COVID-19 vaccine trial Monday, after it became the first US company to start a clinical trial for a vaccine back in March.
This sparked hope that a vaccine for the deadly virus could make it to market by January and sent Wall Street investors into overdrive.
Stocks in Moderna surged as much as 30 percent Monday to $87 a share, and the company’s market value climbed to $29 billion.
While investors raced to get a slice of the firm, the two insiders CFO Kim and CMO Zaks quietly dumped the near-$30 million of shares between them on Monday and Tuesday.
According to filings, Kim also offloaded stocks in the days before the results of the trial were announced, selling 20,000 shares worth $1.3 million on May 15.
The timing of the sales may appear suspicious but Moderna said this week’s sales from the two insiders were executed under automated insider trading plans, known as 10b5-1 plans.
Moderna’s chief financial officer Lorence Kim (left) and chief medical officer Tal Zaks (right) dumped the staggering value of stocks on Monday and Tuesday when the share price skyrocketed following the company’s announcement over its vaccine trial
Such plans lay out future stock trades at set prices or on set dates, with transactions typically being carried out without the insiders taking any action.
‘These transactions are executing automatically pursuant to these trading plans,’ the company said.
Experts have said this means the deals are perfectly legal.
Andrew Gordon, director of research services at Equilar, told CNN Business the executives’ actions would only pose a ‘legal issue if they created or modified their 10b5-1 plan while in possession of material insider information.’
‘It’s not uncommon for insiders to sell shares they own, nor is it bad for them to capitalize on the current stock price.’
The company’s share price wavered more as the week went on as the medical community gave a mixed response to the success of the vaccine trials.
The company’s share price wavered more as the week went on as the medical community gave a mixed response to the success of the vaccine trials. Dr Fauci called the trials ‘optimistic’
Health website cast doubt on the vaccine Tuesday, saying not enough information was available to understand if the phase one trial was a success and sending shares down to $71.67 that day.
Shares fell further to a low of $67.05 Thursday, down 16 percent from its Monday close.
Shares then went up again Friday to $68.60 after Dr Anthony Fauci, the federal government’s top immunologist, said he was ‘cautiously optimistic’ about Moderna’s vaccine.
‘Although the numbers were limited, it was quite good news because it reached and went over an important hurdle in the development of vaccines. That’s the reason why I’m cautiously optimistic about it,’ Fauci said at a CNN town hall on Thursday.
Dr. Carlos del Rio, an Emory University professor of medicine which is testing Moderna’s vaccine, echoed Fauci’s optimism in an interview with CNBC Friday.
‘I am cautiously optimistic. We are developing at a pace that has never been done before,’ he said.
Moderna’s phase one study of 45 participants and measuring the antibodies in eight participants found all eight had developed antibodies to the virus at levels at or above the antibodies found in people who have recovered from COVID-19
‘Trying to think that, a year after a virus has been identified, we will have a vaccine ready to deploy and ready to go into massive distribution, it’s simply mind-boggling to me.
‘I have to be a little cautious and say I hope it happens, but I don’t want to be – I want to make sure we do it the right way.’
Moderna’s phase one study of 45 participants and measuring the antibodies in eight participants found all eight had developed antibodies to the virus at levels at or above the antibodies found in people who have recovered from COVID-19, the company revealed.
It expects to enter phase two trials with 600 participants soon and phase three trials in July.